The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Raltegravir: The First HIV Type 1 Integrase Inhibitor
Abstract
Raltegravir is the first approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor; it targets the strand transfer step of HIV-1 integration. Clinical trials have demonstrated that raltegravir-containing regimens have potent antiretroviral activity and are well tolerated in HIV-1-infected individuals. In antiretroviral treatment-experienced persons with drug-resistant HIV infection, raltegravir-containing treatment with an optimized background regimen was superior to an optimized background regimen alone. In treatment-naive persons, raltegravir was not inferior to efavirenz when the drugs were administered with tenofovir and lamivudine or emtricitabine. Raltegravir is metabolized by glucuronidation, not hepatically; thus, the potential for drug-drug interactions is decreased. Drug resistance, conferred by substitutions in the gene coding for the HIV-1 integrase enzyme, develops relatively frequently after virologic failure. As an antiretroviral drug with a novel mechanism of action, raltegravir is an important advancement in HIV-1 treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131
Espeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J. Y., Young, S., Hamill, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200139397 · Cited by 317
Repair of gaps in retroviral DNA integration intermediates
Yoder, K. E., & Bushman, F. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.11191-11200.2000 · Cited by 209
Murray, J. M., Emery, S., Kelleher, A. D., Law, M., Chen, J., Hazuda, D. J., Nguyen, B.-Y. T., Teppler, H., & Cooper, D. A. (2007) · AIDS · doi:10.1097/qad.0b013e3282f12377 · Cited by 187 · cited 1×
“Other investigators reviewed these data and determined that plasma HIV-1 RNA levels were 70% lower at the initiation of second-phase viral decay for individuals who received raltegravir, compared with individuals who received efavirenz [24].”
Cited by
A Review of the Toxicity of HIV Medications
Margolis, A. M., Heverling, H., Pham, P. A., & Stolbach, A. (2014) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0325-8 · Cited by 348
Eron, J. J., Young, B., Cooper, D. A., Youle, M., DeJesus, E., Andrade-Villanueva, J., Workman, C., Zajdenverg, R., Fätkenheuer, G., Berger, D. S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62041-9 · Cited by 317
Secondary immunodeficiencies, including HIV infection
Chinen, J., & Shearer, W. T. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.040 · Cited by 305
Metadata
- Authors
- Hicks, C., & Gulick, R. M.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-04
- Volume
- 48
- Issue
- 7
- Pages
- 931-939
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2153000646
- Cited by
- 165
- References
- 4
- FWCI
- 12.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.